|
US10130697B2
(en)
|
2010-03-23 |
2018-11-20 |
Wisconsin Alumni Research Foundation (Warf) |
Vaccines comprising mutant attenuated influenza viruses
|
|
JP2014527799A
(ja)
|
2011-08-26 |
2014-10-23 |
ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション |
変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
US10053671B2
(en)
|
2014-06-20 |
2018-08-21 |
Wisconsin Alumni Research Foundation (Warf) |
Mutations that confer genetic stability to additional genes in influenza viruses
|
|
AR102198A1
(es)
|
2014-10-09 |
2017-02-08 |
Regeneron Pharma |
Proceso para reducir partículas subvisibles en una formulación farmacéutica
|
|
TWI710573B
(zh)
|
2015-01-26 |
2020-11-21 |
美商再生元醫藥公司 |
抗伊波拉病毒醣蛋白之人類抗體
|
|
TWI870789B
(zh)
|
2015-08-04 |
2025-01-21 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
|
US11197925B2
(en)
|
2016-02-19 |
2021-12-14 |
Wisconsin Alumni Research Foundation (Warf) |
Influenza B virus replication for vaccine development
|
|
US11542332B2
(en)
|
2016-03-26 |
2023-01-03 |
Bioatla, Inc. |
Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
US20200148750A1
(en)
|
2016-07-21 |
2020-05-14 |
Emory University |
Ebola Virus Antibodies and Binding Agents Derived Therefrom
|
|
US11020686B2
(en)
|
2016-08-16 |
2021-06-01 |
Regeneron Pharmaceuticals, Inc. |
Methods for quantitating individual antibodies from a mixture
|
|
EP3504328A1
(en)
|
2016-08-24 |
2019-07-03 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
|
JP7102401B2
(ja)
|
2016-10-25 |
2022-07-19 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
クロマトグラフィーデータ解析のための方法およびシステム
|
|
CN113512111B
(zh)
*
|
2017-03-10 |
2023-08-15 |
北京天广实生物技术股份有限公司 |
抗埃博拉病毒单克隆抗体、其制备方法及用途
|
|
BR112020000127A2
(pt)
|
2017-07-06 |
2020-07-07 |
Regeneron Pharmaceuticals, Inc. |
método para selecionar um hidrolisado de soja, e, glicoproteína
|
|
US12162925B2
(en)
*
|
2017-09-15 |
2024-12-10 |
The Wistar Institute Of Anatomy And Biology |
DNA-encoded monoclonal antibodies targeting the Ebolavirus glycoprotein
|
|
CA3073935A1
(en)
|
2017-09-19 |
2019-03-28 |
Regeneron Pharmaceuticals, Inc. |
Methods of reducing particle formation and compositions formed thereby
|
|
WO2019084310A1
(en)
|
2017-10-25 |
2019-05-02 |
Yoshihiro Kawaoka |
HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
|
|
MX2020006639A
(es)
|
2017-12-22 |
2020-09-14 |
Regeneron Pharma |
Sistema y metodo para caracterizar las impurezas de un producto farmaceutico.
|
|
RU2686630C1
(ru)
*
|
2017-12-22 |
2019-04-29 |
федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации |
Штаммы гибридных клеток животных Mus. Musculus - продуценты моноклональных антител к белку GP вируса Эбола (subtype Zaire) и моноклональные антитела к белку GP вируса Эбола (subtype Zaire)
|
|
EP3724223A1
(en)
|
2018-01-02 |
2020-10-21 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
|
BR112020013336A2
(pt)
|
2018-01-31 |
2020-12-01 |
Regeneron Pharmaceuticals, Inc. |
produto farmacêutico proteico, métodos para caracterizar as impurezas do produto farmacêutico proteico de alto peso molecular intermediário, para produção de um anticorpo, e para caracterizar as impurezas de fármaco com variação de carga, anticorpo, e, sistema para caracterizar impurezas de fármaco de alto peso molecular intermediário.
|
|
WO2019152607A1
(en)
*
|
2018-01-31 |
2019-08-08 |
The Wistar Institute Of Anatomy And Biology |
Nucleic acid antibody constructs for use against ebola virus
|
|
TW202311746A
(zh)
|
2018-02-02 |
2023-03-16 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
WO2019168774A1
(en)
|
2018-02-28 |
2019-09-06 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for identifying viral contaminants
|
|
CN108373500A
(zh)
*
|
2018-03-12 |
2018-08-07 |
中国科学院微生物研究所 |
一种热稳定性埃博拉治疗性抗体的制备及应用
|
|
HUE065344T2
(hu)
|
2018-03-19 |
2024-05-28 |
Regeneron Pharma |
Mikrochip kapilláris elektroforézis assay-k és reagensek
|
|
US12253490B2
(en)
|
2018-03-19 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
US12259355B2
(en)
|
2018-03-19 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
MA52175A
(fr)
*
|
2018-03-26 |
2021-02-17 |
Regeneron Pharma |
Anticorps anti-pfrh5 et leurs fragments de liaison à l'antigène
|
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
TWI853823B
(zh)
|
2018-07-02 |
2024-09-01 |
美商里珍納龍藥品有限公司 |
自混合物製備多肽之系統及方法
|
|
WO2020014443A1
(en)
*
|
2018-07-12 |
2020-01-16 |
Vanderbilt University |
Pan-ebolavirus neutralizing human antibodies and methods of use therefor
|
|
US12343390B2
(en)
|
2018-08-07 |
2025-07-01 |
Wisconsin Alumni Research Foundation (Warf) |
Recombinant biologically contained filovirus vaccine
|
|
JP7655849B2
(ja)
|
2018-08-20 |
2025-04-02 |
ウィスコンシン アルムニ リサーチ ファンデイション |
ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター
|
|
CN119264211A
(zh)
|
2018-08-27 |
2025-01-07 |
瑞泽恩制药公司 |
拉曼光谱在下游纯化中的应用
|
|
JP7511542B2
(ja)
|
2018-08-30 |
2024-07-05 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
タンパク質複合体を特徴づけるための方法
|
|
CN111138527B
(zh)
*
|
2018-11-06 |
2021-07-30 |
中国人民解放军军事科学院军事医学研究院 |
抗埃博拉病毒糖蛋白gp1亚基的单克隆抗体4f1及应用
|
|
CN111138528B
(zh)
*
|
2018-11-06 |
2021-07-30 |
中国人民解放军军事科学院军事医学研究院 |
特异性结合于埃博拉病毒糖蛋白聚糖帽的单克隆抗体5a8
|
|
CN111138531B
(zh)
*
|
2018-11-06 |
2021-07-30 |
中国人民解放军军事科学院军事医学研究院 |
特异结合于ebov的gp1亚基的单克隆抗体8f9及应用
|
|
CN111138526B
(zh)
|
2018-11-06 |
2021-07-30 |
中国人民解放军军事科学院军事医学研究院 |
一种抗埃博拉病毒糖蛋白gp2亚基的单克隆抗体2g1及应用
|
|
WO2020150491A1
(en)
|
2019-01-16 |
2020-07-23 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing disulfide bonds
|
|
EP3921413A1
(en)
|
2019-02-08 |
2021-12-15 |
Wisconsin Alumni Research Foundation (WARF) |
Humanized cell line
|
|
EA202192422A1
(ru)
|
2019-03-05 |
2021-12-09 |
Ридженерон Фармасьютикалз, Инк. |
Человеческий сывороточный альбумин в составах
|
|
CN114929269A
(zh)
|
2019-05-01 |
2022-08-19 |
威斯康星校友研究基金会(Warf) |
用于疫苗开发的改进的流感病毒复制
|
|
WO2020231992A1
(en)
|
2019-05-13 |
2020-11-19 |
Regeneron Pharmaceuticals, Inc. |
Improved competitive ligand binding assays
|
|
US11807872B2
(en)
|
2019-08-27 |
2023-11-07 |
Wisconsin Alumni Research Foundation (Warf) |
Recombinant influenza viruses with stabilized HA for replication in eggs
|
|
US12297451B1
(en)
|
2019-10-25 |
2025-05-13 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium
|
|
JP6761889B1
(ja)
*
|
2019-11-11 |
2020-09-30 |
株式会社Ｇｓｐエンタープライズ |
抗ヒトＣｒｉｐｔｏ−１抗体
|
|
CA3158119A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous emulsions
|
|
GB201917480D0
(en)
*
|
2019-11-29 |
2020-01-15 |
Univ Oxford Innovation Ltd |
Antibodies
|
|
CN115398236B
(zh)
|
2020-01-21 |
2024-06-11 |
瑞泽恩制药公司 |
用于糖基化的蛋白质的电泳的去糖基化方法
|
|
JP7674369B2
(ja)
*
|
2020-01-24 |
2025-05-09 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
安定な抗体製剤
|
|
KR20210095781A
(ko)
|
2020-01-24 |
2021-08-03 |
주식회사 에이프릴바이오 |
항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
|
|
JP2023511444A
(ja)
|
2020-01-24 |
2023-03-17 |
ウィスコンシン アルムニ リサーチ ファンデイション |
安定化されたｎａを有する組換えインフルエンザウイルス
|
|
BR112022017048A2
(pt)
|
2020-02-26 |
2022-11-16 |
Vir Biotechnology Inc |
Anticorpos contra sars-cov-2 e métodos para usar os mesmos
|
|
WO2021195410A1
(en)
|
2020-03-25 |
2021-09-30 |
Wisconsin Alumni Research Foundation (Warf) |
Recombinant multivalent influenza viruses
|
|
CN116390771A
(zh)
*
|
2020-07-13 |
2023-07-04 |
瑞泽恩制药公司 |
与蛋白中的谷氨酰胺残基缀合的喜树碱类似物及其用途
|
|
WO2022047108A1
(en)
|
2020-08-31 |
2022-03-03 |
Regeneron Pharmaceuticals, Inc. |
Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
|
|
WO2022074630A1
(en)
*
|
2020-10-09 |
2022-04-14 |
Auxilla Pharmaceuticals And Research Llp |
Liquid oral suspension of favipiravir
|
|
WO2022115588A1
(en)
|
2020-11-25 |
2022-06-02 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous membrane emulsification
|
|
KR20230121854A
(ko)
|
2020-12-17 |
2023-08-21 |
리제너론 파아마슈티컬스, 인크. |
단백질-캡슐화 마이크로겔의 제작
|
|
WO2022150809A1
(en)
*
|
2021-01-05 |
2022-07-14 |
Immunome, Inc. |
Antibody cocktail against sars-cov-2 spike protein
|
|
MX2023008527A
(es)
|
2021-01-20 |
2023-07-28 |
Regeneron Pharma |
Metodos para mejorar el valor proteico en cultivo celular.
|
|
JP2024512299A
(ja)
|
2021-03-03 |
2024-03-19 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
タンパク質の粘度を定量及び変更するためのシステム及び方法
|
|
BR112023024984A2
(pt)
|
2021-06-01 |
2024-02-20 |
Regeneron Pharma |
Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
|
|
US20230077710A1
(en)
|
2021-09-08 |
2023-03-16 |
Regeneron Pharmaceuticals, Inc. |
HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
|
|
CA3232463A1
(en)
|
2021-09-20 |
2023-03-23 |
Philip Mellors |
Methods of controlling antibody heterogeneity
|
|
CA3230984A1
(en)
|
2021-10-07 |
2023-04-13 |
Ross BROWNE |
Systems and methods of ph modeling and control
|
|
WO2023059803A1
(en)
|
2021-10-07 |
2023-04-13 |
Regeneron Pharmaceuticals, Inc. |
Ph meter calibration and correction
|
|
TW202330104A
(zh)
|
2021-10-26 |
2023-08-01 |
美商再生元醫藥公司 |
用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法
|
|
AU2023208050A1
(en)
|
2022-01-14 |
2024-07-04 |
Regeneron Pharmaceuticals, Inc. |
Verrucarin a derivatives and antibody drug conjugates thereof
|
|
US20240245779A1
(en)
|
2023-01-25 |
2024-07-25 |
Regeneron Pharmaceuticals, Inc. |
Methods of modeling liquid protein composition stability
|
|
EP4655595A1
(en)
|
2023-01-25 |
2025-12-03 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
|
WO2024163708A1
(en)
|
2023-02-01 |
2024-08-08 |
Regeneron Pharmaceuticals, Inc. |
Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
|
|
EP4669963A2
(en)
|
2023-02-22 |
2025-12-31 |
Regeneron Pharmaceuticals, Inc. |
SYSTEM FITNESS PARAMETERS AND COLUMN AGING
|
|
US20240366471A1
(en)
|
2023-05-01 |
2024-11-07 |
Regeneron Pharmaceuticals, Inc. |
Multidose antibody drug products using phenol or benzyl alcohol
|
|
US20250109905A1
(en)
|
2023-09-29 |
2025-04-03 |
Regeneron Pharmaceuticals, Inc. |
Lyophilization using controlled nucleation
|
|
US20250129117A1
(en)
|
2023-10-18 |
2025-04-24 |
Regeneron Pharmaceuticals, Inc. |
Rapid purification of monoclonal antibody from in-process upstream cell culture material
|
|
US20250145662A1
(en)
|
2023-11-02 |
2025-05-08 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing lipase activity using stress
|
|
WO2025166281A1
(en)
|
2024-02-01 |
2025-08-07 |
Regeneron Pharmaceuticals, Inc. |
Platform for charge-detection mass spectrometry analysis of aavs
|
|
WO2025175164A1
(en)
|
2024-02-16 |
2025-08-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
|
|
TW202602489A
(zh)
|
2024-03-15 |
2026-01-16 |
美商再生元醫藥公司 |
作為經穩定的蛋白質調配物之賦形劑的聚山梨醇酯及聚氧乙烯山梨糖醇酐
|
|
WO2026025028A1
(en)
|
2024-07-26 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Methods of making ultra-high concentrated protein formulations using lyophilization
|
|
CN120943942A
(zh)
*
|
2024-09-12 |
2025-11-14 |
南京诺唯赞生物科技股份有限公司 |
特异性结合hpv的抗体
|
|
WO2026060350A1
(en)
|
2024-09-13 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
|
|
WO2026076201A2
(en)
|
2024-10-03 |
2026-04-09 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools
|
|
WO2026080597A1
(en)
|
2024-10-08 |
2026-04-16 |
Regeneron Pharmaceuticals, Inc. |
Sustained delivery of biologics and non-aqueous manufacture of same
|
|
CN119462912B
(zh)
*
|
2025-01-15 |
2025-08-19 |
中国人民解放军军事科学院军事医学研究院 |
抗埃博拉病毒vp40蛋白的纳米抗体及在病毒检测中的应用
|